Glucose–insulin–potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders

Research Article

Wei-Fang Liang¹  Qin-Fu Han¹  Pei-Yin Jin¹  Xiao-Yan Guo¹  Hai-San Zhang² 

[1] Department of Cardiovascular Medicine, The People’s Hospital of Anyang, Anyang, Henan, China;The Second Affiliated Hospital of Xinxiang Medical University, 453002, Xinxiang, Henan, China;

关键词: Glucose–insulin–potassium;    Acute coronary syndrome;    Meta-analysis;   

DOI  :  10.1186/1471-2261-14-169

 received in 2014-09-05, accepted in 2014-11-18,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundGlucose-insulin-potassium (GIK) has been advocated in the setting of acute coronary syndrome (ACS) to reduce ischemia-related arrhythmias and myocardial injury. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess whether the use of GIK infusions >3 or <3 hours after the onset of symptoms reduce mortality or cardiac arrest.MethodsElectronic databases (Medline, EMBASE, and Cochrane Central Register of Controlled Trials) and references of retrieved articles were searched for RCTs evaluating the effect of GIK infusions, <3 hours or >3 hours after the onset of symptoms, on mortality and/or cardiac arrest. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each outcome.ResultsNine trials were identified and eligible for review. The summary OR for in-hospital mortality was 1.01 (95% CI 0.94 to 1.09), based on 2,542 deaths among 27,294 patients. The subgroup analysis according to the study enrollment time (within 3 hours [OR, 0.77, 95% CI 0.50-1.16], vs. >3 hours [OR, 0.90; 95% CI, 0.67-1.21]) did not reveal any difference in mortality.ConclusionsAdministration of GIK in ACS patients does not significantly reduce mortality whether or not GIK administration >3 or <3 hours after the onset of symptoms.

【 授权许可】

CC BY   
© Jin et al.; licensee BioMed Central Ltd. 2014